These results are supported by a WHO pharmacovigilance database study linking not only TNF inhibitors but also checkpoint inhibitors, imiquimod, alemtuzumab, and ustekinumab with the induction of vitiligo.143. This evidence concerns the gene TNF and vitiligo.